Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.

× No keyword cloud information.

24 in total

1. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.

Authors: Walter Jentzen; Lutz Freudenberg; Ernst G Eising; Wilfried Sonnenschein; Jochen Knust; Andreas Bockisch
Journal: J Nucl Med Date: 2008-05-15 Impact factor: 10.057

Review 2. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis.

Authors: A de Rooij; J P Vandenbroucke; J W A Smit; M P M Stokkel; O M Dekkers
Journal: Eur J Endocrinol Date: 2009-08-11 Impact factor: 6.664

3. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.

Authors: Heribert Hänscheid; Michael Lassmann; Markus Luster; Richard T Kloos; Christoph Reiners
Journal: Endocr Relat Cancer Date: 2009-07-23 Impact factor: 5.678

4. Radioiodine therapy for thyroid volume reduction of large goitres.

Authors: Juliane Bachmann; Carsten Kobe; Seher Bor; Ilka Rahlff; Markus Dietlein; Harald Schicha; Matthias Schmidt
Journal: Nucl Med Commun Date: 2009-06 Impact factor: 1.690

Review 5. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy.

Authors: Søren Fast; Viveque Egsgaard Nielsen; Steen Joop Bonnema; Laszlo Hegedüs
Journal: Eur J Endocrinol Date: 2008-12-23 Impact factor: 6.664

6. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.

Authors: L S Freudenberg; C Frömke; T Petrich; R J Marlowe; W W Koska; W Brandau; E G Eising; E J Knust; A Bockisch; W Jentzen
Journal: Exp Clin Endocrinol Diabetes Date: 2009-10-23 Impact factor: 2.949

7. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer.

Authors: F Capoccetti; B Criscuoli; G Rossi; F Ferretti; C Manni; E Brianzoni
Journal: Q J Nucl Med Mol Imaging Date: 2009-10 Impact factor: 2.346

8. A novel view on dosimetry-related radionuclide therapy: presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma.

Authors: Alexander R Stahl; Lutz Freudenberg; Andreas Bockisch; Walter Jentzen
Journal: Eur J Nucl Med Mol Imaging Date: 2009-02-27 Impact factor: 9.236

9. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.

Authors: Frederik A Verburg; Heribert Hänscheid; Johannes Biko; Maria C Hategan; Michael Lassmann; Michael C Kreissl; Christoph Reiners; Markus Luster
Journal: Eur J Nucl Med Mol Imaging Date: 2009-12-24 Impact factor: 9.236

10. Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?

Authors: James C Sisson; Anca M Avram; Domenico Rubello; Milton D Gross
Journal: Eur J Nucl Med Mol Imaging Date: 2007-04-25 Impact factor: 10.057

10 in total

1. The "reset button" revisited: why high activity ¹³¹I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients.

Authors: Frederik A Verburg; Markus Luster; Luca Giovanella; Michael Lassmann; Carlo Chiesa; Nicolas Chouin; Glenn Flux
Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-16 Impact factor: 9.236

2. EANM procedure guidelines for therapy of benign thyroid disease.

Authors: Marcel P M Stokkel; Daria Handkiewicz Junak; Michael Lassmann; Markus Dietlein; Markus Luster
Journal: Eur J Nucl Med Mol Imaging Date: 2010-07-13 Impact factor: 9.236

3. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases.

Authors: Heribert Hänscheid; Cristina Canzi; Wolfgang Eschner; Glenn Flux; Markus Luster; Lidia Strigari; Michael Lassmann
Journal: Eur J Nucl Med Mol Imaging Date: 2013-04-11 Impact factor: 9.236

4. Comparing pre-therapeutic ¹²⁴I and ¹³¹I uptake tests with intra-therapeutic ¹³¹I uptake in benign thyroid disorders.

Authors: Falk Gühne; Christian Kühnel; Martin Freesmeyer
Journal: Endocrine Date: 2017-03-07 Impact factor: 3.633

5. Exhalation of ¹³¹I after radioiodine therapy: measurements in exhaled air.

Authors: Klaus Schomäcker; Ferdinand Sudbrock; Thomas Fischer; Markus Dietlein; Carsten Kobe; Mark Gaidouk; Harald Schicha
Journal: Eur J Nucl Med Mol Imaging Date: 2011-08-17 Impact factor: 9.236

Review 6. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.

Authors: Lidia Strigari; Mark Konijnenberg; Carlo Chiesa; Manuel Bardies; Yong Du; Katarina Sjögreen Gleisner; Michael Lassmann; Glenn Flux
Journal: Eur J Nucl Med Mol Imaging Date: 2014-06-11 Impact factor: 9.236

7. Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy.

Authors: Mohammad Abuqbeitah; Mustafa Demir; İffet Çavdar; Handan Tanyildizi; Nami Yeyin; Lebriz Uslu-Beşli; Levent Kabasakal; Nazenin İpek Işıkcı; Kerim Sönmezoğlu
Journal: Radiat Environ Biophys Date: 2018-10-08 Impact factor: 1.925

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.